Divalproex Sodium Tablet, Delayed Release
Product Images NDC 50090-7121

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-7121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Divalproex Fig1)

This text appears to be a figure showing two studies (Study 1 and Study 2) comparing the effects of placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) on some measure labeled as "YRS" or "WIRS". The "*" symbol with "p<0.05" possibly indicates a statistically significant difference between the two treatments. Additionally, it provides definitions of PBO (placebo) and DVPX (divalproex sodium delayed-release tablets).*

FDA Label Image

Figure 2 (Divalproex Fig2)

This text provides information about a comparison between Divalproex Sodium Delayed-Release Tablets and Placebo in reducing the number of Reduction in CPS (Central Processing Speed) Rats. The figure represents the percentage of patients showing improvement, no change, or worsening response.*

FDA Label Image

Figure 3 (Divalproex Fig3)

This text represents a chart showing the percentage of patients with different levels of improvement, no change, or worsening in CPS Rate. The chart is divided into High Dose and Low Dose categories.*

FDA Label Image

Figure 4 (Divalproex Fig4)

This text provides information on the mean 4-week Migraine Rates for Placebo and Divalproex Sodium delayed-release tablets in Study 1 and Study 2. It indicates that the mean dose of divalproex sodium delayed-release tablets was 1,087 mg/day, and the dose used in the studies ranged from 500 to 1,000 mg/day.*

FDA Label Image

Chemical Structure (Divalproex Str)

FDA Label Image

Label Image (Lbl500907121)

30 Tablets of Bifla Ayurvedic Supplement.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.